# Safety and Tolerability of Quetiapine in Multiple Sclerosis

> **NCT02087631** · PHASE1,PHASE2 · COMPLETED · sponsor: **University of Calgary** · enrollment: 14 (actual)

## Conditions studied

- Multiple Sclerosis

## Interventions

- **DRUG:** Extended-release quetiapine fumarate

## Key facts

- **NCT ID:** NCT02087631
- **Lead sponsor:** University of Calgary
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-12
- **Primary completion:** 2019-07
- **Final completion:** 2019-07
- **Target enrollment:** 14 (ACTUAL)
- **Last updated:** 2019-10-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02087631

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02087631, "Safety and Tolerability of Quetiapine in Multiple Sclerosis". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT02087631. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*